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ABSTRACT

LIM Kinase 1 (LIMK1), a serine/threonine kinase, modulates actin polymerization and
microtubule assembly. The function of LIMK1 is regulated by kinases that are activated by
Rho and Rac GTPases. LIMK1 is overexpressed in various cancerous cell types and tissues
and its overexpression promotes increased invasion and metastasis of breast and prostate
cancer cells. Membrane-Type Matrix Metalloproteinase 1 (MT1-MMP) is a member of the
zinc-binding collagenase family, which is involved in extracellular matrix breakdown and
activation of secreted MMP-2.

The balance between activation and inhibition of MT1-

MMP and MMP-2 helps maintaining normal extracellular matrix turnover. However, it has
been shown that elevated MT1-MMP expression can cause excessive ECM digestion and
promote tumor invasion and metastasis. Since RhoA and Rac1 have been implicated in
metastasis and invasion along with LIMK1 activation, we investigated a possible link
between LIMK1 and MT1-MMP. Our results show that the level of MT1-MMP expression is
correlated with that of LIMK1 and LIMK1 acts as a transcriptional regulator of MT1-MMP.
Additionally, we show that LIMK1 physically associates with MT1-MMP and promotes its
translocation

to

the

iii

plasma

membrane.
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1. INTRODUCTION
1.1 LIM Kinase 1

LIM Kinase 1 (LIMK1) is a dual specificity serine/threonine and tyrosine kinase

involved in modulating actin and microtubule dynamics.

It is a member of the small

family of LIM domain containing kinases, which also includes LIM Kinase 2. LIMK1 contains
two LIM domains in tandem at the N-terminus, a PDZ domain, and a kinase domain at the Cterminus (Figure 1) [Okano et al., 1995]. LIM domains are zinc -coordinating loops, which are
involved in protein- protein interactions. The residues involved in zinc interactions are
highly conserved while the residues in the center of the loop are more variable and provide
the diversity for specific interactions with different proteins. In addition to the LIM domains,
the PDZ domain is also believed to be involved in mediating protein-protein interactions.
LIMK1 also contains a nuclear localization sequence in its kinase domain along with two
nuclear exit signals in the PDZ domain [Yang and Mizuno, 1999].
Inactive LIMK1 exists in a closed conformation state, which is a result of its LIM
domains associating with its C-terminal kinase domain. Activating phosphorylation at Thr508,
located within the kinase domain, induces a conformational change that allows its kinase
domain to be able to interact with its substrates (Figure 2) [Edwards et al., 1999]. The activity
of LIMK1 is also modulated through association with Hsp90 leading to transphosphorylation
1

and an increased half-life (Figure 2) [Li et al., 2006]. LIMK1 is phosphorylated by kinases that
are activated by the Rho subfamily of small GTPases [Lou et al., 2001].
Two members of the Rho family, Rac1 and Cdc42 mediate activation of LIMK1. Rac1
and Cdc42 in their GTP bound form bind to an inactive PAK1/4 homodimer. This binding
causes the inhibitory domain of one PAK protein to disassociate from the kinase domain of
the other PAK protein [Stofega et al., 2004]. Activated PAK1/4 can then phosphorylate LIMK1,
which promotes formation of lamellipodia and filopodia. In addition to Rac1 and Cdc42,
GTP-bound RhoA also activates LIMK1 through recruitment and activation of Rho kinase
ROCK. Activated ROCK phosphorylates LIMK1 at T508 and activates it [Lin et al., 2003]. The
RhoA signaling pathway induced activation of LIMK1 leads to the formation of actin stress
fibers.Activation of LIMK1 is involved in stabilizing the actin cytoskeleton through the
inactivating phosphorylation

of

Cofilin

at

Ser3

[Arber

et

al.,

1998].

This

phosphorylation prevents Cofilin from severing actin filaments to globular (G) actin and
results in the accumulation of filamentous (F) actin (Figure 2), [Moriyama et al., 1996].
Slingshot Phosphatase functions in opposition to this action by removing the phosphate
group on Cofilin, restoring its activity and causing the increase in G-actin. In addition to
stabilizing actin filaments, LIMK1 can cause a reduction of microtubule stability through its
association with Tubulin-Polymerization Promoting Protein alpha (TPPP-α). The inhibitory
phosphorylation of TPPP-α on serine residues by LIMK1 promotes the disassembly of tubulin
polymers [Acevedo et al., 2007].
2

Figure 1: Structure of LIM Kinase 1
LIM Kinase 1 contains two N-terminal LIM domains, a PDZ domain, and a C-terminal Kinase
domain.

A nuclear localization signal is located in the Kinase domain and two nuclear

exit signals are located in the PDZ domain.
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(Tapia T., 2007)
Figure 2: Activation and Function of LIM Kinase 1

A) GTP bound Cdc42 and Rac1 bind to PAK1 homodimers resulting
in dissociation and transphosphorylation of PAK1. Active PAK1
phosphorylates LIMK1 at T508, causing a conformational change
that activates LIMK1 and allows binding of Hsp90 leading to transphosphorylation and increased stability. B) Phosphorylation of
cofilin at Ser3 by LIMK1 inactivates cofilin. As a result cofilin is
unable to bind to and induce severing of filamentous actin. C)
Dephosphorylation of cofilin by slingshot restores its activity.
Resulting in the disassociation of actin subunits.
4

1.2 Role of LIM Kinase 1 in Cancer Progression

The progression of cancer to a metastatic state is associated with loss of

contact inhibited growth, increased cell mobility, and acquiring the ability to evade the
primary tumor site and invade secondary organs.

Increased activity of Rho GTPases is

noted in a variety of cancers, which results in deregulation of pathways involved in
modulation

of

actin cytoskeleton. Loss of regulation can lead to cell polarization and

induce structures associated with cell mobility and invasion. These processes rely on
stabilized actin filaments to provide the necessary forces need to drive changes in cell
morphology.

The actin depolymerizing family includes the protein cofilin, which is a

known substrate of LIMK1. Inactivation of cofilin by LIMK1 results in local stabilization of
actin filaments. LIMK1 and cofilin localize to focal adhesions and to the membrane ruffles of
lamellipodia at the plasma membrane. Overexpression of LIMK1 is associated with an
invasive cancer and was shown to promote formation of invadopodia.

Although actin

cytoskeleton reorganization is a key step in invasion, degradation of extracellular matrix is
an important initial event that allows tumor cells to escape the primary site, which leads
to distant metastasis. One group of proteolytic proteins integral in these events is the
family members of Matrix Metalloproteinase (MMP). Additionally, increased activity of
Rho signaling cascades are associated with enhanced expression, activation, and localization
of MMPs.
5

1.3 Matrix Metalloproteinases

Matrix metalloproteinases (MMP) are zinc-binding endopeptidases involved in

maintaining the dynamic balance of the extracellular environment through regulated
degradation of the ECM and basement membrane [Kessenbrock et al., 2010].

These

enzymes play diverse roles in tissue remodeling, organ development, inflammation, and
cancer. Twenty three MMP family members that are expressed in humans share common
characteristics including structural elements, Zn dependence, and tight regulation. These
shared structural features include the N-terminal signal peptide, propeptide, catalytic
domain, and a C-terminal hemopexin-like domain connected by a flexible hinge region
[Visse, Nagase, 2003].

The MMP family is sub-classified into two groups: soluble or

membrane associated members.

Membrane associated MMPs, in which MT1-MMP is

classified, have a transmembrane domain ending in a short cytoplasmic tail or instead linked
to a GPI anchor (Figure 3).

MMP regulation begins at the transcriptional level and requires

the activation of transcription factors, including Sp1 and AP-1, to initiate transcription of the
pro-enzymes [Sroka et al., 2007][Benbow et al., 1996]. Like many other proteolytic enzymes,
MMPs are expressed as a zymogen providing additional control over activity. Latent MMP
molecules have the cysteine residue, present in the prodomain, associated with the zinc
ion present at the catalytic site.

This conformation prevents the catalytic domain from

interacting and cleaving its substrates. The cysteine switch mechanism is the next regulatory
6

step that requires the cleavage or modification of the prodomain to activate the MMP [Van
Wart et al., 1990]. Cleavage events for secreted and membrane associated MMPs occur
at different locations.

Both types have their signal sequence cleaved upon entry or

integration into the ER, and are transported through the Golgi to specific areas of the
membrane. Soluble MMPs can then be secreted into the extracellular environment where
processing to the active form occurs.

Alternatively, membrane-associated MMPs are

activated by a convertase during transport and then are tethered to or integrated into the
plasma membrane. Further regulation of MMP activity is modulated by expression of Tissue
Inhibitors of Metalloproteinases (TIMPs). TIMPs bind MMPs and block their active site
inhibiting their catalytic activity, although TIMP2 has an additional role in the activation
of MMP-2.
MMPs participate in normal physiological processes including roles in tissue
remodeling and angiogenesis.

Under normal physiological conditions, MMP activity is

tightly controlled at multiple levels but loss of this regulation can lead to excessive
degradation of the ECM and events associate with cancer progression.

MMPs have long

been linked with cancer and invasion. Early research sought inhibitors to reduce the activity
of these peptidases; unfortunately the inhibitors were not effective in significantly changing
the disease outcome in patients. This may be partially explained by more recent research
showing additional role of MMPs in cancerous tissue beyond degrading basement
membranes. MMPs participate in the complex cross talk between the cancerous tissue and
7

stromal cell and alter intracellular signaling. These findings suggest MMPs can modify
tumor vasculature, inhibit apoptosis, and promote cell proliferation. Additionally, MMPs can
induce epithelial-to-mesenchymal transition (EMT), a hallmark of advanced stage cancers.
One important member of the MMP family is MT1-MMP, also known as MMP-14.
MT1- MMP is anchored to the membrane by its transmembrane domain and positioned with
the catalytic domain in the pericellular space. MT1-MMP has roles in normal development
along with cancer progression. It is found to be overexpressed in a variety of tumor tissues
(Visse et al., 2003). Functions of MT1-MMP include degradation of multiple ECM
components, activation of MMP-2, promotion of cell migration, and regulation of growth
in 3-D tissue environment. With many diverse functions, cells have evolved a complex
means of regulation for MT1-MMP. Starting at the transcriptional level, activation of the
transcription factor Sp1 drives expression of proMT1-MMP. Next, the propeptide is cleaved
in the Golgi by furin convertase producing the active enzyme [Yana et al., 2000] that is
targeted to the plasma membrane. This cleavage along with glycosylation, are speculated to
modulate localization and substrate specificity of MT1- MMP [Wu et al., 2007][Wu et al.,
2004]. The activity of membrane-integrated MT1-MMP undergoes further regulation by
the levels of expressed TIMP2 [Strongin et al., 1995]. Additional regulatory processes
include inactivation by autocatalytic shedding, and endocytosis [Osenkowski et al., 2004].
One of the major functions of MT1-MMP is the proteolytic activation of secreted
proMMP-2. Elevated expressions of MT1-MMP, MMP-2, and MMP-9 are positively
8

correlated with tumor progression, invasiveness, and poor patient survival [Deryugina
et al., 2006]. Activation of proMMP-2 by MT1-MMP requires sub saturation expression
levels of TIMP2. TIMP2 binds and inhibits MT1-MMP but is still free to bind the hemopexinlike domain of proMMP-2.

The resulting MT1-MMP/TIMP2/proMMP-2 complex can now

associate with a neighboring TIMP2-free MT1-MMP molecule through the hemopexin
domains of both MT1- MMP molecules, initiating cleavage of proMMP-2 (Figure 4), [Itoh et
al., 2001]. Furthermore, MT1-MMP/TIMP2/MMP-2 complexes can cleave and activate
secreted proMMP-9, in a TIMP-2 dependent activation cascade starting with MT1-MMP [Toth
et al., 2003].

1.4 Role of MT1-MMP in Cancer Progression
MT1-MMP has many functions in the development of metastatic cancers, and its
expression is associated with increased invasiveness of cancerous cells. Invasion begins at
the invadopodia, similar to lamellipodia, which are specialized membrane protrusions
containing actin scaffolding that penetrate the substrate below. This penetration requires
the degradation of the extracellular matrix by secreted and membrane associated proteases.
An essential mediator of this process, MT1-MMP is localized to these regions, and also
promotes MMP-2 localization through binding to its hemopexin domain [Kim et al. 1998].
MT1-MMP can then degrade multiple ECM substrates including collagens, laminins, and
9

fibronectin. This physically allows the cells to migrate but also reveals cryptic binding sites
on the cell surface that play additional roles. The cleavage of laminin-5 by MT1-MMP
promotes increased cell motility and this effect is amplified by MMP-2, which is activated by
MT1-MMP [Koshikawa et al., 2000]. In addition to cancer cell motility, cleavage of collagenIV reveals a cryptic binding site, which promotes migration of vascular endothelial cells. The
invasion and migration of vascular endothelial cells is a critical event required for
angiogenesis.

Additionally, MT1-MMP can degrade the fibrin matrix surrounding new

vessels [Hiraoka et al., 1998]. This potentially allows for increased sprouting of new vessels
and increased circulation to the tumor. During the development of new vasculature, newly
formed vessels are leaky and have loose cellular junctions especially in the lymphatic vessels.
This increases the ability of cancerous cells to become metastatic by escaping the tumor and
entering circulation. Circulating tumor cells then need to escape the blood vessels and enter
surrounding tissues.

This process is called extravasation and expression of MT1-MMP is

involved in these events {Tsunenzuka et al., 1996].

Extensive research has been

conducted on regulation of expression and functions of MT1-MMP, some of which has
been described, but still many aspects remain to be elucidated. This can partially be
explained by the diverse roles of MT1-MMP and the impact other MMPs have on cell-cell
cross talk.

Although broad-spectrum inhibitors of MMP initially looked promising because

of the structural similarities among MMPs, non- oncogenic MMPs are also inhibited by
these inhibitors. As a result, significant side effects, high toxicity and limited effectiveness of
10

these inhibitors made them failed clinically. New therapeutics needs to be developed with
reduced toxicity, which may be achieved through the inhibition of multiple oncogenic
proteins through combination therapy or inhibiting specific MMP, such as MT1- MMP.
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pro-MMP-2

pro-MT1-MMP
Signal Peptide

Propeptide
Cysteine Switch
Cleavage Site
Catalytic
Domain
Hinge Region
Hemopexin-like
Domain
Transmembrane
Domain
Cytoplasmic Tail
Figure 3: Structural Organization of proMT1-MMP and proMMP-2
Common structural elements shared by MMPs include the signal peptide, propeptide
(containing Cys residue), and Zn binding catalytic domains.
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Figure 4: TIMP2 Mediated Activation of proMMP-2 by MT1-MMP
1) TIMP2 binds and inactivates MT1-MMP, 2) Soluble proMMP-2 binds TIMP2 through its
hemopexin-like domain, 3) A neighboring active MT1-MMP molecule can now associate
with the MMP/TIMP2 complex, 4) The active MT1-MMP interacts with the complexed MT1MMP and initiates cleavage/activation of proMMP-2, 5a) Active MMP-2 disassociates from
complex or 5b) Active MMP-2 remains complexed and activates proMMP-9.

13

1.5 Previous Studies

Earlier studies from our laboratory and others showed overexpression of LIMK1 in

various types of cancerous tissues including cancerous prostate tissue. Differential
expression of LIMK1 also was noted in a variety of prostate cancer (PCa) cell lines and
normal prostate epithelial cells (PrEC). Our studies showed elevated LIMK1 expression in all
cancer cell lines analyzed compared to PrEC (Figure 5). The highest expression of LIMK1 was
noted in the metastatic prostate cancer line PC-3 and a low to moderate level in the Benign
Prostatic Hyperplasia cell line BPH-1. A higher level phosphorylated cofilin, a bona fide LIMK1
substrate was also noted in PC-3 cells compared to BPH-1 cells . To study the function of
LIMK1 BPH-1 cell line was used for ectopic expression of LIMK1. Several constructs were
prepared to express full- length as well as mutant LIMK1. These include: Full length LIMK1;
Kinase-dead LIMK1; or Constitutively-Active LIMK1. Kinase-dead LIMK1 was generated by
mutating Asp460

into an alanine, and Constitutively-Active LIMK1 was generated by

mutating Thr508 into two glutamic acid residues. Our studies further showed that the stable
expression of full length LIMK1 was enough to induce an invasive phenotype in BPH-1 cells
and the partial inhibition of LIMK1 in PC-3 cells using anti-sense RNA reduced the number of
invasive cells [Davila et al. 2003]. Because matrix metalloproteinases (MMPs) are the key
mediators involved in invasion, a possible correlation between LIMK1 expression and MMPs
was studied next. BPH-1 cells expressing constitutively active LIMK1 (BPHLCA) or the control
14

vector (BPHV) were used to study the effect of LIMK1 expression on invasion. These assays
were conducted with or without treatment with a broad-spectrum MMP inhibitor, ilomastat
(GM6001). The results showed that BPHLCA cells had a 4-5-fold increase in the number
of invasive cells, and that this invasion was largely blocked by treatment with the MMP
inhibitor. This data lead us to speculate that a possible relationship exists between LIMK1
expression and MMPs.
To further elucidate this link we monitored the effect of LIMK1 expression on the
secretion of proMMP-2 and proMMP-9. Elevated expression of MMP-2 and MMP-2 has been
correlated with increased malignancy. Secretion of these MMPs was studied next using
Zymography which showed increased gelatinolytic activity of both MMP-2 and MMP-9
in BPHLCA

cells compared to vector expressing cells.

We also noted increased

concentrations of proMMP-2 and active MMP-2 in BPHLCA cells, while MMP-9 only
showed an increase in its latent form. To verify that the increased expression of LIMK1 was
responsible for these results, we monitored MMP-2 and MMP-9 mRNA levels in BPHLCA
compared to vector expressing cells by RT-PCR. We observed a 10 fold increase in MMP-2
mRNA in BPHLCA compared to vector expressing cells, although the levels of MMP-9 mRNA
remained relatively unaffected by LIMK1 expression.

This data suggested a possible

correlation between LIMK1 expression and MT1- MMP, because MT1-MMP is both an
activator of MMP-2 and a target of the inhibitor,ilomastat.

15

Figure 5: LIMK1 is differentially expressed in human prostate cell lines and prostate tissues

a) Immunoblot analysis of LIMK1 in total lysates of human prostate cell lines. b) Expression of
LIMK1 in prostate tissues. Upper panel, Normal/benign areas. Lower panel, cancerous
glands. Upper and lower left, Hematoxylin/eosin-stained slides. Upper and lower right, areas
from normal and cancerous tissues are shown in higher magnification (×200). Arrows
indicate light staining in basal cells in normal/benign areas (upper panel) and intense
staining in cells in cancerous areas (lower panel)
16

1.6 Hypothesis/Objectives

Based on published studies and preliminary experiments conducted in our laboratory, we
hypothesize that LIMK1 is involved in the regulation MT1-MMP. To test our hypothesis we
planned to study
1. The expression of MT1-MMP in cells differentially expressing LIMK1
2. A possible physical association of LIMK1 with MT1-MMP
3. Subcellular localization of LIMK1 and MT1-MMP
4. Effect of LIMK1 expression on MT1-MMP transport and localization
5. Effect of LIMK1 expression on MT1-MMP transcription

17

2. MATERIAL AND METHODS:

2.1 Cell Culture and Cell Lines

The parental BPH-1 cells (a gift for P Narayana, University of Florida) (Hayward et al., 1995)
and its transfected sub-lines, were maintained in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich) with 10% fetal bovine serum and 1% antibiotic/antimycotic (Invitrogen).
BPH-1 cells stably overexpressing constitutively active (phosphomimic) LIMK1 with a Cterminal Flag tag (BPHLCA) and the empty vector control (BPHV) were produced previously

in the lab.

The LIMK1 phosphomimic (T508EE) was produced by site directed mutagenesis.

Stable cells were selected using hygromycin and stable populations were mixed to
prevent clonal bias and continually maintained in media containing hygromycin. PC3 cells
(ATCC) were maintained in F-12 HAM (Sigma-Aldrich) supplemented with 10% fetal bovine
serum, 2mM glutamine, and 1% antibiotic/antimycotic. All cells were in a humidified
atmosphere containing 5% CO2, at 37°C.

2.2 Immunoblot, Immunoprecipitation, and Antibodies

For immunoblots, cells were lysed using RIPA lysis buffer (50mM Tris pH 8.0,

20mM NaCl, 2.5mM EDTA, 1mM PMSF, 1% NP-40, 10ug/mL leupeptin, 10ug/mL aprotinin)
and freeze thaw cycles. 50ug of whole cell extract was separated by SDS-PAGE and subjected
18

to western blotting with the appropriate primary and horseradish peroxidase conjugated
secondary antibodies.

A chemiluminescence kit (Thermo Scientific) was used to detect

target proteins. For immunoprecipitation, cells were lysed as describe above in RIPA lysis
buffer containing a proteinase inhibitor mixture set III (Calbiochem EMD).

LIMK1 or MT1-

MMP was immunoprecipitated from 500ug whole cell lysate using 2ug of the appropriate
primary

antibody

for

4

hours

at

4°C.

Antigen-antibody

complexes

were

immunoprecipitated with 40ul protein A/G PLUS Sepharose beads (Santa cruz) for 16-18
hours at 4°C. Precipitated proteins were detected by immunoblot analysis and described
above.

19

Table 1: Dilutions of antibodies and incubation times

Antibody

Company

Dilution

Incubation
Time/Temperature

Flag

Sigma

1:2000

1hr/RT

LIMK1

BD biosciences

1:100

16hr/4°C

GAPDH

Sigma

1:1000

1hr/RT

MT1-MMP

Neomarker

7ug/ml

16hr/4°C
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2.3 Gene Silencing Using Short Hairpin RNA

LIMK1 expression in PC3 cells was reduced by transfection of HuSH shRNA construct

against LIMK1 (#3: AAGGACAAGA GGCTCAACTTCATCACTGA) in the pGFP-V-RS vector
(Origene Technologies).

Four different shRNA constructs targeting LIMK1 were screened

and the construct with the highest reduction in LIMK1 was used in subsequent
experiments. A non- targeting shRNA construct (scr) was created to control for off target
effects. PC3 cells were transiently transfected with either construct using Lipofectamine
or FuGENE HD for 55-72 hours.

2.4 Dual and Triple Label Immunofluorescence Analysis

Cells were seeded on poly-L-lysine coated coverslips in 24 well dishes and allowed

to attach for 24 hours. For knockdown experiments, PC3 cells were transfected with LIMK1
shRNA or scrambled shRNA 24 hours after seeding and were maintained for an additional
24 hours. For immunostaining, cells were washed with phosphate buffer (0.1M) and fixed in
4% paraformaldehyde at room temperature for 10 minutes. Cells were then washed with
either 0.2% Triton X-100 (BPH) or 0.1% Triton X-100 for 3 min or 0.1% Tween-20 for 4 min
(PC3) in phosphate buffer. Cells were blocked in phosphate buffer containing 10% goat
serum, 0.2% Triton X-100 for 1.5 hours at room temperature. Cells were stained with
primary antibodies diluted in blocking solution for 1 hour at room temperature. Cells were
then washed with blocking solution. Next, cells were stained with fluorophore-conjugated
21

secondary antibodies diluted in blocking solution for 30 minutes at room temperature.
Coverslips were then washed in phosphate buffer containing Triton X-100 or Tween-20 as
described above then post-fixed with 4% paraformaldehyde for 5 minutes at room
temperature. Coverslips were mounted with gel mount (BioMeda) and visualized on a Zeiss
710 confocal microscope. Colocalization values were quantified by selecting specific regions
of singly labeled cells to set the thresholds. The specific regions of interest (vesicles, entire
cell, or entire membrane) were used for pixel quantification. Colocalization was quantified
using Zeiss Zen 2009 software or Olympus FV1- ASW software, which calculates overlap and
colocalization coefficient as derived from Mander’s article based on Pearson’s correlation
coefficient.

The values for the overlap coefficient range from 0 to 1. An Overlap Coefficient with a value of
1 represents perfectly colocalized pixels.

Because each pixel is subtracted by the average pixel intensity, the value for Correlation R
22

can range from -1 to 1. A value of 1 would mean that the patterns are perfectly similar
(colocalized), while a value of -1 would mean that the patterns are perfectly opposite.

23

Table 2: Dilutions of antibodies and incubation times

Primary Antibody

Company

Dilution

Incubation
Time/Temperature

Flag

Sigma

35mg/mL

1hr/RT

LIMK1

BD biosciences

1:50

1hr/RT

MT1-MMP

Neomarker

1:200

1hr/RT

TGN46

Novus Biologicals

1:115

1hr/RT

2⁰
Ab

Company

Dilution

Incubation
Time/Temperature

Cy3

Jackson Labs

1:300

30min/RT

Cy5

Jackson Labs

1:300

30min/RT

Alexa 647

Invitrogen

1:300

30min/RT
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2.5 Dual Luciferase Reporter Assay

Reporter assays were conducted with firefly luciferase driven by a 7.2 KB promoter

fragment of MT1-MMP in a modified pGL3 parent vector (kindly provided by Jorma KeskiOja, University of Helsinki). Cells were co-transfected with this construct and a transcription
control construct containing Renilla luciferase driven by thymidine kinase promoter using
Lipofectamine LTX according to our published protocol (Tapia et al., 2011).

Stably

transfected BPHLCA and BPHV cells and PC3 cells transiently transfected with LIMK1 shRNA
or scrambled shRNA were used.

PC3 cells were harvested 62 hours post-transfection.

Luciferase expression was determined using a Dual luciferase assay kit (Promega) according
to manufacturer’s protocol.

2.6 Statistical Analysis

Quantitative results are presented as mean ± SD of the number of independent
experiments performed. A p value of < 0.05 was considered significant.
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3. RESULTS:

3.1 Expression of MT1-MMP Correlates with the Expression of LIMK1

MT1-MMP expression has been shown to be elevated in tumors of increasing grade

and malignancy, as is the expression of LIMK1. In order to elucidate a possible connection
between the expression of LIM Kinase 1 and MT1-MMP, we first monitored the expression of
MT1-MMP in cells differentially expressing LIMK1. Cell lysates from BPH-1, BPHLCA, and PC-3
were immunoblotted with anti-LIMK1 and anti-MMP antibodies, and expression patterns
were compared. We chose to use an antibody targeting the hinge region of MT1-MMP,
because it recognized all forms of the protein. Our immunoblot results showed that with
increasing concentrations of LIM Kinase 1, cells also expressed increasing levels of MT1-MMP
(Figure 6). Increasing levels of all forms of MT1-MMP such as, latent, active, and
autocatalytic forms were detected. To further confirm these findings, we employed shRNA
mediated down regulation of LIMK1 expression in PC-3 cells.. LIM Kinase inhibition resulted
in the reduced expression of all forms of MT1-MMP as noted by western blots.
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Figure 6: Expression of MT1-MMP correlates with LIMK1 Expression
Immunoblot analysis of LIMK1 and MT1-MMP, in total lysates of BPHV, BPHLCA, and PC-3
cell lines. a) Cells overexpressing LIMK1 display elevated MT1-MMP expression, b) PC-3
cells expressing LIMK1-shRNA display reduced MT1-MMP expression.
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3.2 LIM Kinase 1 Colocalizes & Physically Associates with MT1-MMP

We next investigated whether LIMK1 physically interacts with MT1-MMP using

immunoprecipitation and immunofluorescence analyses. LIMK 1 was immunoprecipitated
using PC-3 cell lysates and immunoblotted with MT1-MMP. Detected polypeptide bands
correlated with both active and latent forms of MT1-MMP. A polypeptide band
corresponding to LIMK1 was also detected in the immunoblots of the reverse
immunoprecipitation, which confirmed a physical association of LIMK1 with MT1-MMP in a
complex (Figure 7). Additionally we noticed that LIMK1 was associating with both latent and
active forms of MT1-MMP.
Next we monitored localization of these proteins within PC-3 and BPHLCA cells
using dual-label immunofluorescence analysis (Figure 8). Our results indicated that both
LIMK1 and MT1-MMP were colocalized in the Golgi area as well as at the periphery of the
cell.

To confirm that these proteins were indeed colocalized, quantitative analysis of

overlapping pixels and intensities was conducted using both Zeiss Zen and Leica LasAF
Software (Figure 9).

The colocalization values were generated on the basis that photons

from both intensities/wavelengths, each wavelength correlating to either LIMK1 or MT1MMP, were striking the same photo detector cell. The generated values strongly suggest a
physical interaction between LIMK1 and MT1-MMP at the Golgi area and at the plasma
28

membrane in both PC-3 and BPHLCA cells. This strengthened the co-immunoprecipitation
results showing that LIMK1 was interacting, directly or indirectly, with both latent and active
MT1-MMP.
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Figure 7: LIMK1 and MT1-MMP Physically Associate
a) Coimmunoprecipitation (Co-IP) and b) Reverse Co-IP of MT1-MMP and LIMK1 using antiLIMK1 (mouse monoclonal) and anti-MT1-MMP (rabbit polyclonal) antibodies and PC3 cell
extracts (500 μg) showing pull down of MT1-MMP and LIMK1 in immunoprecipitates. Nsp
mAb: Nonspecific mouse monoclonal antibodies. Rabbit serum and nonspecific mouse mAb
were used as the negative controls.
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Figure 8: LIMK1 Colocalizes with MT1-MMP
Immunofluorescence analysis of LIMKT508EE and MT1-MMP in BPHLCA (a-c) and PC3 (d-f)
cells. a-c: Co-localization of MT1-MMP (red) and LIMK1 (green)(merged image) in these cells
was mainly to the perinuclear regions at the ER/Golgi area. Colocalization of MT1-MMP with
LIMK1 was also at the plasma membranes (yellow arrows).These cells showed intense
staining and accumulation of LIMK1 in the ruffling membranes (Insert: yellow arrows).
Scale

bar

5

μm.

d-f:Colocalization

of

LIMK1

and

MT1-MMP

in

PC3

cells.

Immunofluorescence analysis of MT1- MMP and LIMK1 showed strong staining of both
proteins in the Golgi areas and in transport vesicles (yellow arrows). Scale bar 5 μm.
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Figure 9: Quantitative Analysis of LIMK1 and MT1-MMP Colocalization
Overlap coefficient of actual pixels in designated areas (red circles) at the Golgi region and
at the membrane for both BPHLCA and PC3 cells.
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3.3 LIMK1 Facilitates MT1-MMP Transport Through the Golgi to the Plasma
Membrane

From the previous results we were able to infer that LIMK1 was indeed interacting

with MT1-MMP, and these interactions were occurring at regions of the cell consistent with
the location of the Golgi network and plasma membrane. To further confirm that these
proteins were indeed colocalized at the Golgi vesicles we employed triple labeled
immunofluorescent analysis using antibodies against TGN46, a Golgi/Trans-Golgi Network
marker. PC-3 cells were labeled with LIMK1, MT1-MMP, and TGN46 antibodies and the
colocalization of LIMK1 with MT1-MMP along with the colocalization of TGN46 with
LIMK1/MT1-MMP was analyzed. The staining patterns of these proteins indicated transport
of all three proteins from the Golgi through the Trans-Golgi vesicles to the membrane (Figure
10). Colocalization of these proteins was analyzed using the Leica LasAF software, which
generated Pearson’s Correlation values for our selected areas of interest. Pearson’s
Correlation values range from -1 to +1, meaning that 0% of either molecule is associating
with the other to 100% association respectively. The Pearson’s Correlation values analyzing
the association of LIMK1 or MT1-MMP with TGN46 at the

Golgi/Membrane

were

as

follows: LIMK1-TGN46 +0.76/+0.71; MT1-MMP-TGN46 +0.63/+0.68. Additionally analysis
of LIMK1 association with MT1-MMP at the Golgi/Membrane generated average Pearson’s
Correlation values of +0.75/+0.80. This data strongly suggests that LIMK1 is associating with
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MT1-MMP at the Golgi and membrane.
To investigate the effect of inhibition of LIMK1 expression on the transport of MT1MMP, PC-3 cells were transfected with either a plasmid expressing LIMK1-shRNA or nontargeting shRNA. After 48 hrs cells were fixed and stained for immunofluorescent
microscopy. The reduction in LIMK1 and MT1-MMP expressions was confirmed by measuring
staining intensities by immunofluorescent-microscopy and by western blotting of the
lysates of PC-3 cells transfected at the same time. Slides were prepared and images were
taken using the exact experimental conditions (antibody concentrations, laser power, gain,
filter settings, etc) between LIMK1 knock-down and control slides. PC-3 cells expressing
LIMK1-shRNA displayed an overall decrease in LIM Kinase 1 and MT1-MMP staining intensity
compared to cells expressing the control shRNA (Figure 11). We also noticed that cells
expressing the LIMK1-shRNA have MT1-MMP staining intensity restricted to the
perinuclear region compared to control shRNA expressing cells.
To verify that reduction in LIMK1 expression correlates with an inhibition of MT1MMP transport to the membrane, we next monitored MT1-MMP intensity at the membrane
and at Golgi vesicles stained with TGN46. Our data showed an overall reduction in cellular
MT1-MMP staining intensity following knockdown of LIMK1 (Figure 12). Specific
quantification of MT1- MMP intensities at Golgi vesicles and at the membrane was then
conducted (Figure 13). PC-3 cells expressing LIMK1-shRNA displayed an average reduction
of 1.8-fold in the intensity of MT1-MMP staining at Golgi vesicle compared to control
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shRNA-expressing cells.

Moreover, the average reduction in MT1-MMP staining was

further decreased at the membrane (3.1 fold). Additionally there was no significant change
in the staining intensity or pattern of TGN46 following LIMK1 knockdown and no significant
change in the colocalization of MT1-MMP with TGN46 at the Golgi or membrane. This
suggests that LIMK1 expression is promoting MT1-MMP transport to the membrane.
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Figure 10: Colocalization of LIMK1 and MT1-MMP at Golgi Vesicles
Immunolocalization of MT1-MMP and LIMK1 showed strong staining of both proteins in
the Golgi areas (White staining and long white arrows) along with Golgi marker: TGN46.
Yellow arrows: Colocalization of MT1-MMP and LIMK1 in Golgi vesicles at various
distances towards plasma membrane. White arrows: Colocalization of MT1-MMP and
LIMK1 to the plasma membrane.
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Figure 11: Reduced Expression of MT1-MMP Following LIMK1 Knockdown in PC-3 Cells
Immunofluorescence and quantitative analysis of the reduction of LIMK1 and MT1-MMP
expression in LIMK1 shRNA but not scrambled RNA expression vector transfected cells.
Immunoblot of transfected PC-3 cell lysate confirms loss in expression of MT1-MMP
following LIMK1 knockdown compared to cells expressing scr shRNA.
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Figure 12: LIMK1 Knockdown in PC-3 Cells Reduces MT1-MMP Expression and Localization
to the Plasma Membrane
Immunofluorescence analysis of MT1-MMP, and TGN46 expression and localization in PC3
cells transfected with scrambled RNA (upper panel) or LIMK1 shRNA (lower panel) expressing
vectors. Upper panel: Yellow arrows: Colocalization of MT1-MMP with TGN46 in Golgi
vesicles moving towards the plasma membrane, White arrow: Targeting of MT1-MMP to the
plasma membrane. Lower panel: Colocalization of MT1-MMP and TGN46 to the perinuclear
region (yellow arrow) but not in the transport vesicles (orange arrow). White arrow:
Transport of TGN46 positive Golgi vesicles to the plasma membrane. No targeting of MT1MMP could be noted in these cells. A significant reduction in the MT1-MMP concentration
was also evident in these cells. Scale: 10 μm.
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Figure 13: Quantification of MT1-MMP Staining Intensities and MT1-MMP/TGN46
Colocalization at Areas of the Membrane and Golgi
Quantitative analysis of the staining intensity of MT1-MMP in the Golgi vesicles (red circles
in DIC merge: yellow arrow) and in the membrane (entire membrane) in scrambled RNA
and LIMK1 shRNA transfected PC3 cells. Pearson’s correlation coefficient analysis confirms
colocalization between MT1-MMP and TGN46 in Golgi vesicles at the same region used for the
analysis of staining intensity.
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3.4 LIMK1 Expression Promotes Surface Expression of MT1-MMP

Our immunofluorescent microscopy data showed a correlation between LIMK1

expression and MT1-MMP localization to the membrane. Surface labeling of MT1-MMP
was next employed to verify if indeed surface localization of MT1-MMP is regulated by
LIMK1. Surface MT1-MMP expression was first monitored in BPHLCA cells expressing
constitutively active LIMK1, or in control BPHV cells. Non-permeabilized cells were labeled
with antibodies against MT1-MMP, to stain only active MT1-MMP on the plasma membrane.
FITC-conjugated secondary antibodies were used monitor labeled cells by Flow Cytometry.
BPHLCA cells displayed an increased number of MT1-MMP positive stained cells along with
an increase in average fluorescence compared to BPHV cells. This can be visualized by the
increase in peak height and the shift towards the right, respectively, in stained BPHLCA cells
compared to stained BPHV cells (Figure 14).
We next examined the effect of LIMK1 knock down on MT1-MMP surface expression
in PC-3 cells by biotin labeling. PC-3 cells expressing either LIMK1-shRNA or control shRNA,
with intact membranes, were incubated with Sulfo-NHS-Biotin, a membrane impermeable
biotin ester. In the presence of primary amine groups, the biotin molecule is transferred to
the amine group, which results in the biotinylation of all surface proteins. The cells were
then lysed, and biotinylated proteins were enriched through immunoprecipitation with
strepavidin beads. The immunoprecipitates were resolved by SDS-PAGE and transferred to
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a PVDF membrane to be blotted with the anti-MT1-MMP antibodies. Our results showed
that PC-3 cells transfected with LIMK1-shRNA had reduced levels of biotin labeled MT1MMP.

These results show that LIMK1 expression positively correlates with the surface

expression

of

MT1-MMP
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(Figure

15).

Figure 14: LIMK1 Expression Positively Regulates Surface Localization of MT1-MMP in BPH
Cells
A) Flow cytometric analysis of MT1-MMP cell surface expression in transfected BPH

cell lines. Two-parameter histogram of the surface staining of MT1-MMP with

fluorescence intensities in the X-axis and number of cells in the Y-axis in BPH cells

expressing LIMK1. Black histogram represents unstained cells. Red histogram

represents population of fluorescent cells within each sample. B) Quantitative analysis
of fluorescent cells. For densitometric analysis, the BPHLCA cells that were emitting
fluorescence were gated out from the nonfluorescent cells and calculated as the

percentage of the fluorescent control (BPHV) cells. Data represents the mean ± SD of
three independent experiments. *P =0.0005.
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Figure 15: Inhibition of LIMK1 Expression Reduces Surface Localization of MT1- MMP in PC3 Cells
A) Surface biotinylation of MT1-MMP following knock down of LIMK1 in PC3 cells.
Immunoblot of biotinylated MT1-MMP in the streptavidin bead bound MT1-MMP. Lane 1
non-biotinylated cells, Lane 2: control shRNA expressing cells, Lane 3: LIMK1 shRNA
expressing cells. B) Immunoblot analysis of LIMK1 in PC3 cells expressing control shRNA or
LIMK1 shRNA used for surface biotinylation assays. Data show representative images of
three independent experiments.
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3.5 Expression of LIMK1 is Associated with Increased Transcriptional Activation of MT1MMP

The expression of matrix-metalloproteinases including MT1-MMP is up-regulated in

advanced prostate cancer tissues and invasive PCa cell lines. MT1-MMP expression has
been correlated with the aggressiveness of prostate cancer cell types and shown to be
overexpressed in the invasive PCa cell line PC-3. In PC-3 cells, MT1-MMP transcription is
regulated through AKT/JNK signaling, leading to activation of the transcription factor Sp1.
Additionally, treatment with bone morphogenic protein 2 was shown to activate PI3K/AKT
signaling leading to PAK1/4 phosphorylation and activation of LIMK1. These reports suggest
a possible link between LIMK1 activity and MT1-MMP transcription.

To elucidate any

connection with LIMK1 activity, we used prostate cells differentially expressing LIMK1 and
monitored MT1-MMP promoter activity using a dual luciferase reporter assay. The Firefly
luciferase reporter vector was constructed with the full 7.2kb MT1-MMP promoter
positioned to drive the expression of Firefly luciferase. The MT1- MMP reporter vector was
co-transfected with a plasmid constitutively expressing Renilla luciferase into BPHLCA and
BPHV cells along with PC-3 cells expressing LIMK1-shRNA, control shRNA, or only expressing
the luciferase reporter vectors. Firefly luciferase activity was measured by the light emitted
and these values were normalized to Renilla luciferase activity to compensate for
inconsistencies in transfection and transcription efficiencies (Figure 16). BPHLCA displayed a
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3-4 fold increase in relative Firefly luciferase activity compared to BPHV cells. This suggests
that LIMK1 activity positively correlates with MT1-MMP transcriptional activation.
Furthermore, the knockdown of LIMK1 resulted in significant (95%) and consistent reduction
in luciferase activity compared to PC-3 cells expressing only the luciferase reporter vectors.
PC-3 cells expressing the control shRNA displayed some off target effects but LIMK1-shRNA
cells still displayed reduced luciferase activity.

Although, the luciferase activity of cells

expressing the control shRNA was similar to the other LIMK1-shRNA vectors tested, which
were not effective in reducing LIMK1 expression. This shows that the results generated
using the LIMK1-shRNA in all of the experiments is not a consequence of off target effects.
These observations indicate that MT1-MMP transcription is increased with increased
expression of LIM Kinase 1.
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Figure 16: Effect of LIMK1 on transcription activation of MT1-MMP
A) Relative luciferase activity in BPHLCA and BPHV cells transfected with MT1-MMP
promoter luciferase constructs. B) Relative luciferase activity in PC3 cells transfected with
MT1-MMP promoter luciferase construct alone or in combination with scrambled shRNA or
LIMK1 shRNA expressing plasmids. Results show Mean ± SD of at least three separate
experiments. *P =0.0075 (BPHLCA vs. BPHV), **P = 0.004 (PC3 scr shRNA vs. PC3LIMK1
shRNA),***P

=

0.0005

(PC3
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vs.

PC3LIMK1

shRNA).

4. DISCUSSION
The organization and modulation of actin filaments are key processes in cell motility
and change in cell morphology. Formation of the membrane structures, lamellipodia,
filopodia, and invadopodia, require the temporal and spatial regulation of proteins involved in
actin cytoskeleton stability and organization.

Abnormal regulation cytoskeletal dynamics

would predispose cells to adopting characteristics associated with invasive and metastatic
cancers. The Rho family of GTPases participates in signaling pathways affecting actin
organization and was shown to have increased activity in advanced cancers. A downstream
effector of this pathway is LIMK1, which is activated by Rho/ROCK signaling. Expression of
LIMK1 has been linked with advanced metastatic cancers and shown to promote invasion
in cancer cell lines. Additionally, activity of Rho family members, RhoA and Rac1, promotes
expression and activation of MMPs involved in invasion and metastasis.

Enhanced

expression of MT1-MMP is correlated with tumor progression and malignancy.
Our studies presented here reveal a role for LIMK1 in the complex regulatory
scheme of MT1-MMP. The functions of MT1-MMP in metastatic events are well described.
Therefore, it is very plausible that the ability of LIMK1 to promote cell migration and invasion
is facilitated by activation of MMPs. Our preliminary results confirmed the participation of
MT1-MMP, MMP-2, and MMP-9 in the LIM Kinase 1 induced invasion of the benign
prostatic hyperplasia cell line, (BPHLCA).

The broad inhibitor of MMP activity,
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ilomastat/GM6001, significantly reduced the number of invasive cells induced by LIMK1
expression.

This study is the first to report the novel functional association between

LIMK1 and MT1-MMP.
To further investigate the link between LIMK1 and MMP, we first asked if LIMK1
expression was increasing the enzymatic activity of MMPs. Our results showing increased
processing of MMP-2 in BPHLCA cells addresses this question. Furthermore, these cells had
elevated secretion of both proMMP-2 and proMMP-9, a common phenomenon noted in
prostate cancer patients.

We next explored the possibility that LIMK1 expression was

modulating the transcription of these MMPs.

Our findings showed a significantly higher

transcription of MMP-2 in LIMK1 expressing cells. These results lead us to investigate a
possible connection between LIMK1 and a known activator of MMP-2, MT1-MMP.
From our immunoblot results we noted an enhanced expression of MT1-MMP in
prostate cell lines over-expressing LIMK1. This effect was reversed when LIMK1 expression
was reduced by LIMK1-shRNA in PC-3 cells.

Upon further investigation into this

relationship, we identified, through co-immunoprecipitation that LIMK1 was physically
associating with active and latent forms of MT1-MMP. This suggests a possible association
before and after processing of MT1-MMP in the Golgi. We next monitored the locations of
these interactions with immunofluorescent microscopy. These results showed colocalization,
verified by strong Pearson’s correlation values, occurring in the Golgi, Trans-Golgi vesicles,
and at the cell cortex. Furthermore, colocalization at Golgi vesicles at varying distances
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from the perinuclear area to the cell membrane suggests a role of LIMK1 in regulating
vesicular trafficking of MT1-MMP.

To confirm this speculation, we inhibited LIMK1

expression in PC-3 cells and noted an overall reduction of MT1-MMP expression although
this reduction was greater at the membrane than at the Golgi.

Taken together, with

previous reports on the role of LIMK1 in modulating Golgi vesicles and endocytic vesicles,
strengthens the argument for the involvement of LIMK1 in regulating membrane expression
of MT1-MMP (Rosso et al., 2004)(Nishimura et al., 2006). Confirmation that LIMK1 was
indeed involved in the surface expression of MT1-MMP came from our surface labeling
experiments.

Using flow cytometry we monitored the effect of enhanced expression of

LIMK1 in BPH-1 cells, which revealed an increase in surface labeled MT1-MMP.
Conversely, the effect of reduced LIMK1 expression in PC-3 cells was monitored by
immunoprecipitation of biotinylated surface proteins, which were then immunoblotted
for MT1-MMP expression. These immunoblots show reduced MT1-MMP concentrations in
the immunoprecipitates of cells expressing LIMK1 shRNA.
Finally our study showed that LIMK1 expression was involved in regulating the
transcriptional activity of MT1-MMP. We employed the full length MT1-MMP promoter,
containing a known Sp1 binding site, to drive transcription of Firefly Luciferase. We were
than able to quantify the effect of LIMK1 expression on MT1-MMP transcription by
monitoring the relative activity of Firefly luciferase. Although the effect of LIMK1 on MT1MMP transcription was clearly observable, the underlying mechanism remains to be
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elucidated.

However the importance of this study lies in the possibility that, through

regulation of MMPs, LIMK1 may be a more effective therapeutic target without the toxicity
of

inhibitors

of
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MMP

activity.
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